MSCs-Exos / AbelZeta Pharma - LARVOL DELTA

A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS (clinicaltrials.gov) - P1/2 | N=18 | Completed | Sponsor: Ruijin Hospital | Recruiting ➔ Completed | N=169 ➔ 18

Enrollment change • Trial completion • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer's disease: a phase I/II clinical trial. (PubMed, Gen Psychiatr) - P1/2 | "Intranasal administration of ahaMSCs-Exos was safe and well tolerated, and a dose of at least 4×10 particles could be selected for further clinical trials. NCT04388982."

Journal • P1/2 data • Stroma • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Developmental Disorders

Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study. (PubMed, Stem Cell Res Ther) - P1 | "Our trial shows that a consecutive 5 days inhalation dose of clinical grade haMSC-Exos up to a total amount of 2.0 × 10 nano vesicles was feasible and well tolerated in seven COVID-19 patients, with no evidence of prespecified adverse events, immediate clinical instability, or dose-relevant toxicity at any of the doses tested. This safety profile is seemingly followed by CT imaging improvement within 7 days. Further trials will have to confirm the long-term safety or efficacy in larger population."

Journal • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • IL6

A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS (clinicaltrials.gov) - P1/2; N=169; Recruiting; Sponsor: Ruijin Hospital; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

the Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients With Alzheimer's Disease (clinicaltrials.gov) - P1/2; N=9; Recruiting; Sponsor: Ruijin Hospital; Trial completion date: Apr 2022 ➔ Aug 2022; Trial primary completion date: Apr 2021 ➔ Aug 2021

Clinical • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Dementia • MRI

A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS (clinicaltrials.gov) - P1/2; N=169; Not yet recruiting; Sponsor: Ruijin Hospital

Clinical • New P1/2 trial • Acute Respiratory Distress Syndrome • Respiratory Diseases

the Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients With Alzheimer's Disease (clinicaltrials.gov) - P1/2; N=9; Recruiting; Sponsor: Ruijin Hospital; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Alzheimer's Disease • CNS Disorders • Dementia

A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia (clinicaltrials.gov) - P1; N=24; Completed; Sponsor: Ruijin Hospital; Not yet recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

the Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients With Alzheimer's Disease (clinicaltrials.gov) - P1/2; N=9; Not yet recruiting; Sponsor: Ruijin Hospital

Clinical • New P1/2 trial • Alzheimer's Disease • CNS Disorders • Dementia • Reperfusion Injury